The Power of Innovation Centres in US Healthcare

By HEOR Staff Writer

November 4, 2023

Healthcare Innovation Centres

Unveiling the Potential of Healthcare Innovation Centres


A growing trend in US healthcare systems, innovation centres are creating waves in the sector. These centres, which prioritise the quick creation, operationalisation, and assessment of novel innovations—many of which are digital—are transforming the healthcare industry. They are usually developed in response to issues that healthcare systems encounter, with a shared emphasis on problem-solving and real-time healthcare delivery.

These centres focus on three main areas: rapidly testing, assessing, and scaling domestic initiatives; disseminating creative, effective ideas throughout the healthcare system; and creating new solutions and ideas from data, experiences, and activities. Innovation centres can provide excellent, hyperlocal research and quality improvement when they are operating at peak efficiency.



The Success and Sustainability of Innovation Centres


However, it’s estimated that up to 90% of industry innovation centres fail. Despite this, healthcare innovation centres have seen significant growth in the past decade. The key to their success and sustainability lies in how they define their value and success.


Innovation centres often focus on demonstrating value in a creative way, rather than commercialisation of innovations. They add value to their institutions through their projects and innovations. For instance, they may create a decision support tool in the electronic health record to identify patients who smoke upon hospital admission. This not only benefits the patients but also the institution by meeting quality metrics.

These centres also offer value by “failing fast”, spending less money to understand whether a project or innovation will or will not work. This sets them apart from the wider healthcare organisation, which tends to be slower and more cautious.

Centres for healthcare innovation can become sustainable entities within US healthcare institutions. However, they must work effectively with their institutions to define success more broadly than purely financial return on investment. The field needs to develop more robust means of measuring these nonfinancial benefits for long-term success.

Reference url

Recent Posts

Joint Scientific Consultation EU
Joint Scientific Consultation EU Strategies for Medical Device Companies

By João L. Carapinha

June 19, 2026

The EU Joint Scientific Consultation gives medical device developers a voluntary route to obtain targeted feedback on clinical evidence plans well before formal Joint Clinical Assessment and national reimbursement decisions. Manufacturers of select high-risk technologies can align their developme...
EU Joint Clinical Assessment
Insights on EU Joint Clinical Assessment for High-Risk Medical Devices

By João L. Carapinha

June 19, 2026

EU Joint Clinical Assessment is a distinct, harmonised process that operates separately from CE marking. It produces comparative clinical evidence on selected high-risk devices to support more consistent national reimbursement decisions across EU member states. Insights from the
LesionAttn Skin Cancer AI
LesionAttn Skin Cancer AI Enhances Fairness in Dermatological Diagnostics

By João L. Carapinha

June 19, 2026

LesionAttn Skin Cancer AI tackles a critical flaw in current skin cancer detection tools: models that unconsciously rely on background skin features differing between men and women, producing unequal accuracy across genders. By steering neural networks to focus on the actual lesion instead of the...